Skip to main content
Caplight Logo









ART BioScience

ART BioScience

Private
IsraelHealthcare & Life Scienceshttps://www.artbioscience.com/

Last Round

Series B

Jul 29, 2025

Total Funding Raised

$245M

Company Overview

ART BioScience is a biotechnology company that develops mRNA-based therapeutics and gene-editing therapies for the treatment of Duchenne muscular dystrophy and other rare genetic disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

mRNA therapeuticslipid nanoparticleLNPDuchenne Muscular DystrophyDMDgene editingCRISPR-Cas9protein replacement therapydrug delivery technologygenetic medicinebiotech startuporphan diseasedrug discoverypre-clinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ART BioScience Comparables

Compare ART BioScience with similar companies based on industry and business-model similarity.

ART BioScience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Spot Biosystems
82%
MyoGene Bio
77%
Entrada Therapeutics
70%

ART BioScience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJul 29, 2025
Series ADec 7, 2023
SeedJun 1, 2023

ART BioScience Investors

Notable investors and investment history

ART BioScience investors
InvestorRounds
Omega FundsSeries A, Series B, Seed
B Capital GroupSeries B
Alexandria Venture InvestmentsSeries B
F-Prime CapitalSeries A, Series B, Seed
Sofinnova InvestmentsSeries B
Qatar Investment AuthoritySeries B
Third Rock VenturesSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 29, 2025

    $132M round led by B Capital Group and Sofinnova Investments.

  • Dec 7, 2023

    $90M round led by Third Rock Ventures

ART BioScience Filings

Explore SEC and related filing metadata, where available.

ART BioScience filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ART BioScience's valuation, stock price, and market status.

Is ART BioScience a public or private company?

ART BioScience is a private company.

What is the current stock price of ART BioScience?

ART BioScience is a private company with no public stock price. No recent secondary market data is available.

How much is ART BioScience worth (valuation)?

Valuation information for ART BioScience is not publicly available.

Can I buy ART BioScience stock?

ART BioScience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ART BioScience's last funding round?

ART BioScience's most recent funding round was Series B on July 29, 2025.

Who are the main investors in ART BioScience?

Key investors in ART BioScience include Omega Funds, B Capital Group, F-Prime Capital, Sofinnova Investments, Third Rock Ventures.

Will ART BioScience IPO soon?

No public IPO plans have been announced for ART BioScience.

How can I track ART BioScience secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ART BioScience's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersIsrael
Year Founded2015
Last FundingJul 29, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?